Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
dc.contributor.author | Herold, Kevan C. | |
dc.contributor.author | Reynolds, Jesse | |
dc.contributor.author | Dziura, James | |
dc.contributor.author | Baidal, David | |
dc.contributor.author | Gaglia, Jason | |
dc.contributor.author | Gitelman, Stephen E. | |
dc.contributor.author | Gottlieb, Peter A. | |
dc.contributor.author | Marks, Jennifer | |
dc.contributor.author | Philipson, Louis H. | |
dc.contributor.author | Pop‐busui, Rodica | |
dc.contributor.author | Weinstock, Ruth S. | |
dc.date.accessioned | 2021-01-05T18:46:41Z | |
dc.date.available | WITHHELD_11_MONTHS | |
dc.date.available | 2021-01-05T18:46:41Z | |
dc.date.issued | 2020-11 | |
dc.identifier.citation | Herold, Kevan C.; Reynolds, Jesse; Dziura, James; Baidal, David; Gaglia, Jason; Gitelman, Stephen E.; Gottlieb, Peter A.; Marks, Jennifer; Philipson, Louis H.; Pop‐busui, Rodica ; Weinstock, Ruth S. (2020). "Exenatide extended release in patients with type 1 diabetes with and without residual insulin production." Diabetes, Obesity and Metabolism 22(11): 2045-2054. | |
dc.identifier.issn | 1462-8902 | |
dc.identifier.issn | 1463-1326 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/163873 | |
dc.description.abstract | AimsTo test whether a long- acting GLP- 1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to determine whether the drug would affect beta cell function.MethodsWe performed a randomized placebo- controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C- peptide. Seventy- nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C- peptide levels. The primary outcome was the difference in glycated haemoglobin (HbA1c) levels at 24- weeks. Participants were followed for another 6 months off study drug.ResultsAt week 24, the time of the primary outcome, the least squares (LS) mean HbA1c level was 7.76% (95% confidence interval [CI] 7.42, 8.10) in the exenatide ER group versus 8.0% (95% CI 7.64, 8.35) in the placebo group (P = 0.08). At week 12 the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group versus 8.05% (95% CI 7.7, 8.4) in the placebo group (P = 0.01). The improvement at week 12 was driven mainly by those with detectable levels of C- peptide. Those treated with exenatide ER lost weight at 12 and 24- weeks compared to those treated with placebo (P- <0.001 and P = 0.007). The total insulin dose was lower, but not when corrected for body weight, and was not affected by residual insulin production. Adverse events were more frequent with exenatide ER, but hypoglycaemia was not increased.ConclusionTreatment with exenatide ER may have short- term benefits in some individuals with T1D who are overweight or who have detectable levels of C- peptide, but short- term improvements were not sustained. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | C- peptide | |
dc.subject.other | glucagon- like peptide- 1 receptor agonist | |
dc.subject.other | type 1 diabetes | |
dc.subject.other | adjunctive therapy | |
dc.title | Exenatide extended release in patients with type 1 diabetes with and without residual insulin production | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Public Health (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163873/1/dom14121_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163873/2/dom14121.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163873/3/dom14121-sup-0001-Supinfo.pdf | |
dc.identifier.doi | 10.1111/dom.14121 | |
dc.identifier.source | Diabetes, Obesity and Metabolism | |
dc.identifier.citedreference | Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin- 4) on glycemic control over 30- weeks in sulfonylurea- treated patients with type 2 diabetes. Diabetes Care. 2004; 27 ( 11 ): 2628 - 2635. | |
dc.identifier.citedreference | Drucker DJ. The ascending GLP- 1 road from clinical safety to reduction of cardiovascular complications. Diabetes. 2018; 67 ( 9 ): 1710 - 1719. | |
dc.identifier.citedreference | Drucker DJ. Mechanisms of action and therapeutic application of glucagon- like Peptide- 1. Cell Metab. 2018; 27 ( 4 ): 740 - 756. | |
dc.identifier.citedreference | Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open- label, non- inferiority study. Lancet. 2008; 372 ( 9645 ): 1240 - 1250. | |
dc.identifier.citedreference | Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin- 4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88 ( 7 ): 3082 - 3089. | |
dc.identifier.citedreference | Husain M, Donsmark M, Bain SC. Oral Semaglutide and cardiovascular outcomes in type 2 diabetes. Reply. N Engl J Med. 2019; 381 ( 21 ): 2076 - 2077. | |
dc.identifier.citedreference | Oram RA, Jones AG, Besser RE, et al. The majority of patients with long- duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014; 57 ( 1 ): 187 - 191. | |
dc.identifier.citedreference | Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ss- cell turnover after 50- years of diabetes: Joslin Medalist Study. Diabetes. 2010; 59 ( 11 ): 2846 - 2853. | |
dc.identifier.citedreference | Xu G, Stoffers DA, Habener JF, Bonner- Weir S. Exendin- 4 stimulates both beta- cell replication and neogenesis, resulting in increased beta- cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999; 48 ( 12 ): 2270 - 2276. | |
dc.identifier.citedreference | Sherry NA, Chen W, Kushner JA, et al. Exendin- 4 improves reversal of diabetes in NOD mice treated with anti- CD3 monoclonal antibody by enhancing recovery of beta- cells. Endocrinology. 2007; 148 ( 11 ): 5136 - 5144. | |
dc.identifier.citedreference | Sims EK, Bahnson HT, Nyalwidhe J, et al. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. 2019; 42 ( 2 ): 258 - 264. | |
dc.identifier.citedreference | Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014; 37 ( 3 ): 666 - 670. | |
dc.identifier.citedreference | Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat- to- target randomized trial. Diabetes Care. 2016; 39 ( 10 ): 1702 - 1710. | |
dc.identifier.citedreference | Ahren B, Hirsch IB, Pieber TR, et al. Efficacy and safety of Liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016; 39 ( 10 ): 1693 - 1701. | |
dc.identifier.citedreference | Johansen NJ, Dejgaard TF, Lund A, et al. Efficacy and safety of meal- time administration of short- acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double- blind, placebo- controlled trial. Lancet Diabetes Endocrinol. 2020; 8 ( 4 ): 313 - 324. | |
dc.identifier.citedreference | Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and IV glucose challenges. Diabetes Care. 2014; 37 ( 1 ): 210 - 216. | |
dc.identifier.citedreference | Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti- CD3 mAb) treatment preserves C- peptide responses in patients with new- onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013; 62: 3766 - 3774. | |
dc.identifier.citedreference | Professional Practice Committee. Standards of medical care in diabetes- 2019. Diabetes Care. 2019; 42 ( Suppl 1 ): S3. | |
dc.identifier.citedreference | Lachin JL. Statistical considerations in the intent- to- treat principle. Control Clin Trials. 2000; 21 ( 5 ): 526. | |
dc.identifier.citedreference | Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004; 5 ( 3 ): 445 - 464. | |
dc.identifier.citedreference | Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta- cell function in long- standing type 1 diabetes. Diabetes Care. 2009; 32 ( 12 ): 2251 - 2257. | |
dc.identifier.citedreference | Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Anti- inflammatory potentials of incretin- based therapies used in the management of diabetes. Life Sci. 2020; 241: 117152. | |
dc.identifier.citedreference | Durning SP, Preston- Hurlburt P, Clark PR, Xu D, Herold KC. Type 1 diabetes TrialNet study G. the receptor for advanced glycation endproducts drives T cell survival and inflammation in type 1 diabetes mellitus. J Immunol. 2016; 197 ( 8 ): 3076 - 3085. | |
dc.identifier.citedreference | Elnour AA, Al Hajri N, El Khidir IY, Al Amoodi A, Ahmed SA, Sadeq A. Glucagon- like peptide- 1 receptor agonists cardio- protective effects: an umbrella review. Curr Diabetes Rev. 2020; 16. https://doi.org/10.2174/1573399816666200522214554. | |
dc.identifier.citedreference | van der Aart- van der Beek AB, van Raalte DH, Guja C, et al. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials. Diabetes Obes Metab. 2020. https://doi.org/10.1111/dom.14067. | |
dc.identifier.citedreference | Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon- like peptide- 1 receptor agonists in patients with type 2 diabetes: a meta- analysis. Lancet Diabetes Endocrinol. 2018; 6 ( 2 ): 105 - 113. | |
dc.identifier.citedreference | Thomas MC. The potential and pitfalls of GLP- 1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 2017; 43 ( Suppl 1 ): 2S20 - 2S27. | |
dc.identifier.citedreference | Rawshani A, Sattar N, Franzen S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register- based cohort study. Lancet. 2018; 392 ( 10146 ): 477 - 486. | |
dc.identifier.citedreference | Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008- 2010. JAMA. 2015; 313 ( 1 ): 37 - 44. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.